Impact of rash development for patients with non-small cell lung cancer receiving PD-1/PD-l1- based immune checkpoint inhibitor therapy

2^nd International Conference on Cancer Biology and Therapeutics

June 17, 2024 | Rome, Italy

Yongsheng Yang

Chongqing Red Cross hospital ,China

Scientific Tracks Abstracts: J Oncol Transl Res

Abstract :

Background: Immune-related skin rash is common in patients receiving PD-1/PD-L1-based immune checkpoint inhibitor therapy. This study aimed to explore whether development of rash is predicative of outcomes in patients with non-small cell lung cancer receiving PD-1/PD-L1-based immune checkpoint inhibitor therapy Methods: Relevant data from 299 patients with non-small cell lung cancer receiving PD-1/PD-L1-based immune checkpoint inhibitor therapy during April 2019 to June 2021 were retrospectively collected and analyzed. All patients were followed with the primary endpoints of overall survival and progression-free survival. The Kaplan-Meier curve and Cox regression model were used for data analysis. Results: Skin rash was observed in 47 (15.72%) patients. During a median follow-up time of 40 (IQR 30-49) months, 187 and 82 patients developed progression and died, respectively. The Kaplan-Meier curve showed that the overall survival (42 [IQE 33-50] vs 31 [IQR 22-35], P=0.008) and progression-free survival (30 [IQE 23-36] vs 18 [IQR 13-25], P=0.004) were significantly longer in those with skin rash than those without. However, development of skin rash does not have independent prognostic significance for overall survival (HR=1.11 [95% CI 0.89-1.43], P=0.48) and progression-free survival (HR=1.23 [95% CI 0.93-1.50], P=0.18) in the fully adjusted Cox model. Conclusions: Although the development of skin rash may indicate robust immune response, it does not have independent prognostic significance for patients with non-small cell lung cancer receiving PD-1/PD-L1-based immune checkpoint inhibitor therapy.

Biography :

Yongsheng Yang is a doctor-in-charge in the Chongqing Red Cross hospital (People's Hospital of Jiangbei District). He is working in the Department of Oncology and Hematology. He was born in 1985 and working for therapy and diagnosis of lung cancer for years.